DMTN
DMTN (dematin actin binding protein, also known as DMT and EPB49) is a membrane-cytoskeleton-associated protein that binds and bundles F-actin. It stabilises the spectrin-actin network at the erythrocyte membrane and also acts in fibroblasts and platelets. Browse Assay Genie's current range of DMTN research reagents below, or read on for the biology behind the target.
DMTN is a membrane-cytoskeleton-associated protein with F-actin-binding activity that induces the formation and stabilisation of F-actin bundles. Its bundling activity is reversibly regulated by phosphorylation by the cAMP-dependent protein kinase A (PKA). In erythrocytes, dematin binds the glucose transporter-1 SLC2A1/GLUT1, and in this way stabilises and attaches the spectrin-actin network to the plasma membrane. It helps maintain the functional integrity of PKA-activated erythrocyte shape and the mechanical properties of the membrane.
Beyond red cells, DMTN modulates actin dynamics in fibroblasts, where it acts as a negative regulator of the RhoA activation pathway. In platelets it regulates internal calcium mobilisation across the dense tubular system, which affects granule secretion and aggregation. It is also required for the formation of cell protrusions such as filopodia and lamellipodia, which platelets need for spreading, motility and migration. DMTN is described as a tumour suppressor that inhibits malignant cell transformation.
The DMTN gene encodes a protein of the villin/gelsolin family. It has a core domain at the N-terminus and a headpiece domain at the C-terminus that binds F-actin. Purified from erythrocytes, the protein exists as a trimer of two 48 kDa polypeptides and one 52 kDa polypeptide; the subunits arise from alternative splicing in the 3' coding region that includes the headpiece domain. Alternative splicing yields multiple transcript variants and isoforms. The former name was erythrocyte membrane protein band 4.9 (dematin). Disruption of the gene has been correlated with autosomal dominant Marie Unna hereditary hypotrichosis, and loss of heterozygosity is thought to contribute to prostate cancer progression.
DMTN links the spectrin-actin network to the red cell membrane via GLUT1, making it central to studies of erythrocyte shape and membrane mechanics.
DMTN bundles and stabilises F-actin in a PKA-regulated manner and negatively regulates RhoA activation in fibroblasts.
DMTN regulates calcium mobilisation, granule secretion, aggregation and protrusion formation, supporting platelet spreading, motility and migration.
DMTN acts as a tumour suppressor, and loss of heterozygosity at the gene is thought to play a role in prostate cancer progression.
DMTN binds F-actin and induces its bundling and stabilisation, with activity regulated by PKA phosphorylation. In erythrocytes it attaches the spectrin-actin network to the membrane through GLUT1. It also modulates actin dynamics in fibroblasts and platelets, and acts as a tumour suppressor.
DMTN is also called dematin, DMT and EPB49, and was formerly named erythrocyte membrane protein band 4.9 (dematin). Alternative splicing in the 3' coding region, where the headpiece domain lies, produces multiple transcript variants and isoforms, including the 48 kDa and 52 kDa subunits found in erythrocytes.
Disruption of the DMTN gene has been correlated with autosomal dominant Marie Unna hereditary hypotrichosis, and loss of heterozygosity is thought to contribute to prostate cancer progression. A mouse ortholog, Dmtn, exists; check the datasheet of any product for its validated reactivity.
Other villin/gelsolin family members, actin-cytoskeleton and erythrocyte membrane proteins, and Rho pathway targets with products at Assay Genie.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q08495; product specifications from Assay Genie datasheets.